Matches in SemOpenAlex for { <https://semopenalex.org/work/W2483008971> ?p ?o ?g. }
- W2483008971 endingPage "3656" @default.
- W2483008971 startingPage "3650" @default.
- W2483008971 abstract "The clinical efficacy of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD) plus ponatinib has not been compared with that of HCVAD plus dasatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in a randomized clinical trial.The authors analyzed 110 patients with newly diagnosed Ph+ ALL who were enrolled in 2 consecutive, prospective, phase 2 clinical trials of frontline HCVAD with either dasatinib (63 patients) or ponatinib (47 patients). Propensity score analysis with 1:1 matching with the nearest neighbor matching method and inverse probability of treatment weighting (IPTW) analysis based on the propensity scores were performed to assess response rates, event-free survival (EFS), and overall survival (OS) between the cohorts.Propensity score matching identified 41 patients in each cohort. With propensity score matching, the 3-year EFS rates for patients treated with HCVAD plus ponatinib and HCVAD plus dasatinib were 69% and 46%, respectively (P =.04), and the 3-year OS rates were 83% and 56%, respectively (P =.03). IPTW analysis using prematching cohorts demonstrated that patients treated with HCVAD plus ponatinib had significantly higher rates of minimal residual disease negativity by flow cytometry on day 21, complete cytogenetic response at complete response, major molecular response at complete response and at 3 months, and complete molecular response at 3 months. IPTW confirmed that treatment with HCVAD plus ponatinib was associated with longer EFS (P =.003) and OS (P =.001) compared with treatment with HCVAD plus dasatinib.The clinical outcome of patients treated with HCVAD plus ponatinib appears to be superior to that of patients treated with HCVAD plus dasatinib among individuals with Ph+ ALL. Cancer 2016;122:3650-6. © 2016 American Cancer Society." @default.
- W2483008971 created "2016-08-23" @default.
- W2483008971 creator A5000750846 @default.
- W2483008971 creator A5006104041 @default.
- W2483008971 creator A5015140142 @default.
- W2483008971 creator A5020340537 @default.
- W2483008971 creator A5021380291 @default.
- W2483008971 creator A5022647201 @default.
- W2483008971 creator A5029750735 @default.
- W2483008971 creator A5038307470 @default.
- W2483008971 creator A5049173793 @default.
- W2483008971 creator A5049385583 @default.
- W2483008971 creator A5059600583 @default.
- W2483008971 creator A5061026876 @default.
- W2483008971 creator A5083803570 @default.
- W2483008971 creator A5084801772 @default.
- W2483008971 creator A5088307376 @default.
- W2483008971 creator A5090435894 @default.
- W2483008971 date "2016-08-01" @default.
- W2483008971 modified "2023-10-15" @default.
- W2483008971 title "Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis" @default.
- W2483008971 cites W1506738181 @default.
- W2483008971 cites W1673031009 @default.
- W2483008971 cites W1784814409 @default.
- W2483008971 cites W1838408716 @default.
- W2483008971 cites W1972060994 @default.
- W2483008971 cites W1993808217 @default.
- W2483008971 cites W2013779251 @default.
- W2483008971 cites W2016088019 @default.
- W2483008971 cites W2030796837 @default.
- W2483008971 cites W2033862877 @default.
- W2483008971 cites W2036193982 @default.
- W2483008971 cites W2047597898 @default.
- W2483008971 cites W2065851457 @default.
- W2483008971 cites W2070520252 @default.
- W2483008971 cites W2110648386 @default.
- W2483008971 cites W2118502261 @default.
- W2483008971 cites W2124174337 @default.
- W2483008971 cites W2139499066 @default.
- W2483008971 cites W2150291618 @default.
- W2483008971 cites W2296061031 @default.
- W2483008971 cites W2406225326 @default.
- W2483008971 cites W2544051485 @default.
- W2483008971 cites W2599899418 @default.
- W2483008971 doi "https://doi.org/10.1002/cncr.30231" @default.
- W2483008971 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5321539" @default.
- W2483008971 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27479888" @default.
- W2483008971 hasPublicationYear "2016" @default.
- W2483008971 type Work @default.
- W2483008971 sameAs 2483008971 @default.
- W2483008971 citedByCount "145" @default.
- W2483008971 countsByYear W24830089712016 @default.
- W2483008971 countsByYear W24830089712017 @default.
- W2483008971 countsByYear W24830089712018 @default.
- W2483008971 countsByYear W24830089712019 @default.
- W2483008971 countsByYear W24830089712020 @default.
- W2483008971 countsByYear W24830089712021 @default.
- W2483008971 countsByYear W24830089712022 @default.
- W2483008971 countsByYear W24830089712023 @default.
- W2483008971 crossrefType "journal-article" @default.
- W2483008971 hasAuthorship W2483008971A5000750846 @default.
- W2483008971 hasAuthorship W2483008971A5006104041 @default.
- W2483008971 hasAuthorship W2483008971A5015140142 @default.
- W2483008971 hasAuthorship W2483008971A5020340537 @default.
- W2483008971 hasAuthorship W2483008971A5021380291 @default.
- W2483008971 hasAuthorship W2483008971A5022647201 @default.
- W2483008971 hasAuthorship W2483008971A5029750735 @default.
- W2483008971 hasAuthorship W2483008971A5038307470 @default.
- W2483008971 hasAuthorship W2483008971A5049173793 @default.
- W2483008971 hasAuthorship W2483008971A5049385583 @default.
- W2483008971 hasAuthorship W2483008971A5059600583 @default.
- W2483008971 hasAuthorship W2483008971A5061026876 @default.
- W2483008971 hasAuthorship W2483008971A5083803570 @default.
- W2483008971 hasAuthorship W2483008971A5084801772 @default.
- W2483008971 hasAuthorship W2483008971A5088307376 @default.
- W2483008971 hasAuthorship W2483008971A5090435894 @default.
- W2483008971 hasBestOaLocation W24830089712 @default.
- W2483008971 hasConcept C126322002 @default.
- W2483008971 hasConcept C143998085 @default.
- W2483008971 hasConcept C17923572 @default.
- W2483008971 hasConcept C2776694085 @default.
- W2483008971 hasConcept C2776755627 @default.
- W2483008971 hasConcept C2777583451 @default.
- W2483008971 hasConcept C2778461978 @default.
- W2483008971 hasConcept C2778729363 @default.
- W2483008971 hasConcept C2779429289 @default.
- W2483008971 hasConcept C2779536868 @default.
- W2483008971 hasConcept C2779823535 @default.
- W2483008971 hasConcept C2780381907 @default.
- W2483008971 hasConcept C71924100 @default.
- W2483008971 hasConceptScore W2483008971C126322002 @default.
- W2483008971 hasConceptScore W2483008971C143998085 @default.
- W2483008971 hasConceptScore W2483008971C17923572 @default.
- W2483008971 hasConceptScore W2483008971C2776694085 @default.
- W2483008971 hasConceptScore W2483008971C2776755627 @default.
- W2483008971 hasConceptScore W2483008971C2777583451 @default.
- W2483008971 hasConceptScore W2483008971C2778461978 @default.
- W2483008971 hasConceptScore W2483008971C2778729363 @default.